References
- Poplack D., Reaman G., Belyer A., et al. Central nervous system preventive therapy with high-dose methotrexate in acute lymphoblastic leukemia. ASCO Proc 1984; 3: 204
- Abromowitch M., Ochs J., Pui C. H., Fairclough D., Murphy S. B., Rivera G. K. Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: analysis by contemporary risk classifications. Blood 1988; 71: 866–869
- Hryniuk W. N., Bertino J. R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical biochemical correlates. J. Clin. Invest. 1969; 48: 2140–2155
- Ettinger L. J., Chervinsky D. S., Freeman A. I., Creaven P. J. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin lymphoma. Cancer 1982; 50: 1676–1682
- Evans W. E., Hutson P. R., Stewart C. F., et al. Methotrexate cerebrospinal lluid and serum concentrations after intermediate-dose methotrexate infusion. Clin. Pharmacol. Ther. 1983; 3: 301–307
- Maurus R., Boilletot A., Otten J. Treatment of acute lymphoblastic leukemia in children with the BFM protocol; a cooperative study and analysis of prognostic factors. Haematol. Blood Transf. 1987; 30: 466–470
- Borsi J. D., Sagen E., Romslo I., et al. 7-hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia. Cancer Chem. Pharmacol. 1990; 27: 164–172
- Thyss A., Milano G., Deville A., et al. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur. J. Cancer Clin. Oncol. 1987; 23: 843–847
- Borsi J. D., Moe P. J. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 1987; 60: 5–13
- Shapiro W. R., Young D. F., Mehta B. M. Methotrexate distribution in cerebrospinal fluid after intravenous ventricular and lumbar injections. N. Engl. J. Med. 1975; 161–166
- Evans W. E., Crom W. R., Stewart C. F., et al. Methotrexate systemic clearance influences probability of relapse in children with standard risk acute lymphoblastic leukemia. Lancet 1984; 359–362
- Evans W. E., Stewart C. F., Huston P. R., et al. Disposition of intermediate dose methotrexate in children with acute lymphoblastic leukemia. Drug Intel. Clin. Pharm. 1982; 5: 839–842
- Borsi J. D., Moe P. J. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 1987; 60: 3020–3024
- Tubergen D. G., Gilchrist G. S., O'Brien R. T., et al. Prevention of CNS disease in intermediate risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy. J. Clin. Oncol. 1993; 11: 520–526